- English (USA)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Monte Rosa Therapeutics Inc (GLUE)
Assess today's live Monte Rosa Therapeutics Inc (GLUE) share price, performance and insights using our live NASDAQ: GLUE stock exchange data.
Analyse the historical data and Monte Rosa Therapeutics Inc share price performance charts on this page. Our technical summary section provides analysis on Monte Rosa Therapeutics share price buy/sell indicators using real-time data (or discuss the Monte Rosa Therapeutics (GLUE) stock price today with other investors in the Monte Rosa Therapeutics NASDAQ share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NASDAQ GLUE share price (ISIN: US61225M1027) to enhance your trading decisions with our free investment tools and resources.
What Is the Monte Rosa Therapeutics Inc Share Price Today?
The Monte Rosa Therapeutics share price today is 16.48.
What Is the Stock Symbol for Monte Rosa Therapeutics Inc
The stock symbol (or 'ticker') for Monte Rosa Therapeutics Inc is "GLUE."
What Stock Exchange Does Monte Rosa Therapeutics Inc Trade On?
Monte Rosa Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Monte Rosa Therapeutics Inc a Good Stock to Buy?
Determining whether Monte Rosa Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and other essential metrics.
Analyse the historical data and Monte Rosa Therapeutics Inc share price performance charts on this page. Our technical summary section provides analysis on Monte Rosa Therapeutics share price buy/sell indicators using real-time data (or discuss the Monte Rosa Therapeutics (GLUE) stock price today with other investors in the Monte Rosa Therapeutics NASDAQ share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NASDAQ GLUE share price (ISIN: US61225M1027) to enhance your trading decisions with our free investment tools and resources.
What Is the Monte Rosa Therapeutics Inc Share Price Today?
The Monte Rosa Therapeutics share price today is 16.48.
What Is the Stock Symbol for Monte Rosa Therapeutics Inc
The stock symbol (or 'ticker') for Monte Rosa Therapeutics Inc is "GLUE."
What Stock Exchange Does Monte Rosa Therapeutics Inc Trade On?
Monte Rosa Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Monte Rosa Therapeutics Inc a Good Stock to Buy?
Determining whether Monte Rosa Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and other essential metrics.
NASDAQ
Currency in USD
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
15.94
17.04
52 wk Range
3.50
19.17
GLUE is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
15.9417.04
52 wk Range
3.5019.17
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
GLUE Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Neutral
Analysts Sentiment
Strong Buy
Price Target
22.70
Upside
+37.74%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
5 analysts have revised their earnings downwards for the upcoming period
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Strong Buy
Moving Averages
Sell
Monte Rosa Therapeutics Company Profile
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body’s natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of neurologic and systemic autoimmune and inflammatory diseases; and MRT-8102 for the treatment of inflammatory diseases driven by IL-1b and the NLRP3 inflammasome. In addition, it develops CDK2 to treat multiple cancers, including ovarian, endometrial, gastric and breast. Further, its pipeline includes programs in immunology and inflammation indications, oncology, cardiovascular, metabolic, and genetic diseases. The company also develops QuEEN, a discovery engine, to enable its target-centric MGD discovery and development approach and its rational design of MGD product candidates. It has a strategic collaboration and licensing agreement with F. Hoffmann-La Roche Ltd. to discover and develop MGDs against targets in cancer and neurological diseases. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.
Monte Rosa Therapeutics Inc Earnings Call Summary for Q4/2024
- Monte Rosa projects strong cash runway into 2028, maintaining robust liquidity with a current ratio of 6.03
- Phase I results for VAV1 program show significant protein degradation and cytokine inhibition
- Strategic collaboration with Novartis announced; expansion in prostate cancer studies planned
- Revenue of $60.64M beats forecast of $51.19M by 18.4%; EPS not disclosed
- IND submission for MRT-8102 program planned for H1 2024; prostate cancer study data expected in H2 2024
Last Updated: 20/03/2025, 13:22
Read Full TranscriptCompare GLUE to Peers and Sector
Metrics to compare | GLUE | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipGLUEPeersSector | |
|---|---|---|---|---|
P/E Ratio | 51.2x | −2.4x | −0.6x | |
PEG Ratio | 0.45 | 0.08 | 0.00 | |
Price/Book | 4.4x | 2.6x | 2.6x | |
Price / LTM Sales | 5.9x | 9.5x | 3.2x | |
Upside (Analyst Target) | 33.5% | 14.5% | 41.8% | |
Fair Value Upside | Unlock | 5.8% | 5.1% | Unlock |
Analyst Ratings
8 Buy
0 Hold
0 Sell
Ratings:
8 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 22.70
(+37.74% Upside)
Earnings
Latest Release
Nov 06, 2025
EPS / Forecast
-0.33 / -0.36
Revenue / Forecast
12.77M / 7.77M
People Also Watch
FAQ
What Is the Monte Rosa Therapeutics (GLUE) Share Price Today?
The live Monte Rosa Therapeutics share price today is 16.48
What Stock Exchange Does Monte Rosa Therapeutics (GLUE) Trade On?
Monte Rosa Therapeutics is listed and trades on the Nasdaq Stock Exchange.
What Is the Ticker (Stock Symbol) for Monte Rosa Therapeutics?
The stock symbol (also called a 'ticker') for Monte Rosa Therapeutics is "GLUE."
What Is the Current Monte Rosa Therapeutics Market Cap?
As of today, Monte Rosa Therapeutics market capitalisation is 1.07B.
What Is Monte Rosa Therapeutics's (GLUE) Earnings Per Share (TTM)?
The Monte Rosa Therapeutics EPS is currently 0.25 (Trailing Twelve Months).
When Is the Next Monte Rosa Therapeutics Earnings Date?
Monte Rosa Therapeutics's next earnings report will be released on 12 Mar 2026.
Is GLUE a Buy or Sell From a Technical Analyst Perspective?
Based on today's Monte Rosa Therapeutics moving averages and other technical indicators, the daily buy/sell signal is Neutral.
How Many Times Has Monte Rosa Therapeutics Stock Split?
Monte Rosa Therapeutics has split 0 times. (See the GLUE stock split history page for full effective split date and price information.)
How Many Employees Does Monte Rosa Therapeutics Have?
Monte Rosa Therapeutics has 147 employees.
What is the current trading status of Monte Rosa Therapeutics (GLUE)?
As of 24 Dec 2025, Monte Rosa Therapeutics (GLUE) is trading at a price of 16.48, with a previous close of 16.48. The stock has fluctuated within a day range of 15.94 to 17.04, while its 52-week range spans from 3.50 to 19.17.
What Is Monte Rosa Therapeutics (GLUE) Price Target According to Analysts?
The average 12-month price target for Monte Rosa Therapeutics is USD22.7, with a high estimate of USD27.5 and a low estimate of USD16. 8 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +37.74% Upside potential.
What Is the GLUE After Hours Price?
GLUE's last after hours stock price is 16.97, the stock has decreased by 0.49, or 2.97%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.